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H I G H L I G H T S

G R A P H I C A L

A B S T R A C T

• The VELIA trial assessed the PARPi
veliparib, combined with frontline chemotherapy and continued as maintenance monotherapy.
• Within the BRCA wild type population,
survival outcomes were improved regardless of homologous recombination
status.
• During chemotherapy, radiographic and
CA-125 responses were numerically
higher with veliparib vs control in all
subgroups.
• PARPi could beneﬁt a broader patient
population than those currently eligible
based on prior Phase 3 trials.
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a b s t r a c t
Objective. In the Phase 3 VELIA trial (NCT02470585), PARP inhibitor (PARPi) veliparib was combined with
ﬁrst-line chemotherapy and continued as maintenance for patients with ovarian carcinoma enrolled regardless
of chemotherapy response or biomarker status. Here, we report exploratory analyses of the impact of homologous recombination deﬁcient (HRD) or proﬁcient (HRP) status on progression-free survival (PFS) and objective
response rates during chemotherapy.
Methods. Women with Stage III-IV ovarian carcinoma were randomized to veliparib-throughout, veliparibcombination-only, or placebo. Stratiﬁcation factors included timing of surgery and germline BRCA mutation status. HRD status was dichotomized at genomic instability score 33. During combination therapy, CA-125 levels
were measured at baseline and each cycle; radiographic responses were assessed every 9 weeks.
Results. Of 1140 patients randomized, 742 had BRCA wild type (BRCAwt) tumors (HRP, n = 373;
HRD/BRCAwt, n = 329). PFS hazard ratios between veliparib-throughout versus control were similar in both
BRCAwt populations (HRD/BRCAwt: 22.9 vs 19.8 months; hazard ratio 0.76; 95% conﬁdence interval [CI]
0.53–1.09; HRP: 15.0 vs 11.5 months; hazard ratio 0.765; 95% CI 0.56–1.04). By Cycle 3, the proportion with
≥90% CA-125 reduction from baseline was higher in those receiving veliparib (pooled arms) versus control
(34% vs 23%; P = 0.0004); particularly in BRCAwt and HRP subgroups. Complete response rates among patients
with measurable disease after surgery were 24% with veliparib (pooled arms) and 18% with control.
Conclusions. These results potentially broaden opportunities for PARPi utilization among patients who would
not qualify for frontline PARPi maintenance based on other trials.
© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).

patients with platinum-sensitive disease or speciﬁc biomarkers [15].
VELIA, therefore, provides a unique opportunity to investigate PARPinhibition effects on a broader patient population and the opportunity
to assess the impact of combining PARP inhibition with chemotherapy.
To better understand how to utilize this unique regimen to treat
newly diagnosed ovarian cancer, we performed an exploratory analysis
with two goals: ﬁrst, to evaluate the contribution of veliparib to ﬁrstline chemotherapy (and maintenance) in BRCA wild type (BRCAwt) cancers with various levels of genomic instability as assessed using the
Myriad myChoice® CDx assay (Myriad Genetics, Inc., Salt Lake City,
UT); and second, to explore whether the addition of veliparib to the chemotherapy phase impacted treatment response. As the number of early
(during chemotherapy) PFS events was small in VELIA, analyses of PFS
precluded a meaningful comparison between those who only received
veliparib with chemotherapy (and not as maintenance) versus chemotherapy alone. Therefore, we conducted analyses exploring the added
beneﬁt of veliparib using potentially more sensitive measures (cancer
antigen 125 [CA-125] and radiographic responses) during the ﬁrst six
cycles of treatment.

1. Introduction
Poly (ADP-ribose) polymerase (PARP) enzymes facilitate the repair
of deoxyribonucleic acid (DNA) damage [1,2]. Cancers with defects in
genes involved in homologous recombination repair, such as the breast
cancer susceptibility genes BRCA1 and BRCA2 (BRCA), are particularly
sensitive to PARP inhibition [3,4] reﬂecting reliance of these cancer
cells on PARP-mediated replication fork stabilization and alternative
end-joining in the absence of homologous recombination. Deﬁning
these and other categories of homologous recombination deﬁciency
(HRD) or proﬁciency (HRP) beyond loss of BRCA function could expand
utilization of PARP inhibitors (PARPi) to cancers with related molecular
defects. Beyond BRCA mutations, only a few HRD biomarkers have been
prospectively tested in PARPi trials and their correlation with PARPi sensitivity has varied across trial design and cancer type [5–7].
Veliparib is an oral PARP-1/PARP-2 inhibitor that has demonstrated
activity as a monotherapy in patients with ovarian carcinoma associated
with germline BRCA mutations [8,9]. Preclinical studies have shown that
PARP inhibition enhances sensitivity of neoplastic cells to DNAdamaging agents [10–14]. Combining chemotherapy with a PARPi
might, therefore, provide therapeutic beneﬁt and enhance antitumor
activity beyond cancers with HRD. The VELIA study (NCT02470585)
was an international, placebo-controlled, three-arm Phase 3 study that
assessed the efﬁcacy of veliparib when added to ﬁrst-line chemotherapy
with or without continued veliparib maintenance (veliparib-throughout and veliparib-combination only) in patients with previously untreated Stage III or IV high-grade serous ovarian, peritoneal, or
fallopian tube carcinoma (HGSC) [15]. The veliparib-throughout regimen led to signiﬁcantly longer progression-free survival (PFS) compared with chemotherapy alone, but no improvement in PFS was
observed with chemotherapy plus veliparib followed by placebo maintenance [15]. The PFS beneﬁt with veliparib-throughout was seen in
each of the primary analytical cohorts: 1) patients with germline or somatic BRCA mutations; 2) patients with HRD, including BRCA mutated
(BRCAm) cases; and 3) intention-to-treat (ITT) population [15]. Exploratory analyses in the HRP population showed effects on PFS that were
smaller, but directionally consistent with those of the primary analysis
(hazard ratio 0.81, 95% CI 0.60 to 1.09) [15].
Prior studies with other PARPi, as frontline maintenance post chemotherapy selectively enrolled patients with a clinical response to
platinum-based chemotherapy, BRCA mutations, or both [5,16,17]. In
contrast, VELIA enrolled patients at diagnosis and did not select for

2. Materials and methods
2.1. Study design
Full details of the study design, inclusion and exclusion criteria,
treatment, and endpoints have been previously published [15].
Women aged ≥18 years with a diagnosis of HGSC were randomized
1:1:1 to receive either carboplatin/paclitaxel (C/P) plus placebo,
followed by placebo maintenance (control arm); C/P plus veliparib,
followed by placebo maintenance (veliparib-combination–only
arm); or C/P plus veliparib, followed by veliparib maintenance
(veliparib-throughout arm). Stratiﬁcation factors for randomization
have been described previously, and included timing of surgery received and residual disease status after primary surgery [15]. HRD
status (independent of BRCA status) was not a prospective stratiﬁcation factor.
The study protocol was approved by all relevant institutional review boards prior to study initiation. The trial was conducted according to International Conference on Harmonisation Good Clinical
Practice guidelines, regulations governing clinical study conduct,
and the Declaration of Helsinki. All participants provided written
informed consent.
246

E.M. Swisher, C. Aghajanian, D.M. O'Malley et al.

Gynecologic Oncology 164 (2022) 245–253

2.2. HRD assessment

2.6. Statistical analysis

Homologous recombination status was assessed using the Myriad
myChoice CDx assay, which combines BRCA tumor mutation sequencing
and assessment of three measures of genomic instability: loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions
[7,18]. These three measures are combined into a genomic instability
score (GIS). HRD was deﬁned as GIS ≥33 or the presence of deleterious
germline or somatic BRCA mutation. HRP was deﬁned as GIS <33 and
the absence of a detectable BRCA mutation, consistent with previous
analyses [19].
BRCA mutation status was evaluated using the Myriad BRACAnalysis
CDx® or myChoice CDx assay for blood (germline) and tissue (somatic
and germline) mutations, respectively.

CIs for response rates were calculated using the normal approximation to the binomial distribution. PFS was estimated using the Kaplan
−Meier method. Stratiﬁed Cox proportional-hazards models were
used to estimate hazard ratios and 95% CIs, and treatment arms were
compared via stratiﬁed log-rank tests. For analysis of PFS by HRD status,
stratiﬁcation factors were International Federation of Gynecology and
Obstetrics stage and residual disease status (no visible residual disease
vs any [>1 cm] residual disease). Hazard ratios and 95% CIs for the
veliparib-throughout versus control arms were calculated for all GIS
using generalized additive model with Cox proportional hazards. The
analysis of PFS in patients with SD following combination treatment
was stratiﬁed by residual disease, stage of disease, choice of paclitaxel
dosing regimen, and BRCA status. This was a post-hoc subgroup analysis
and is potentially biased. Formal hypothesis testing was not performed.
CA-125 response and radiographic responses were analyzed for the
combination phase. During this time, treatment in the veliparibcontaining arms was identical; therefore, these arms were pooled for response analysis. The number and percentage of patients having each
type of response were summarized for the control arm and for both
veliparib arms combined. A proportion test was used to compute the
one-sided P-value comparing the ratio of patients with a CA-125 response in the treatment arm with respect to the control arm. No formal
comparisons were made for ORR. All analyses were exploratory in
nature; statistics are therefore descriptive only.

2.3. PFS assessment
The data cutoff for this analysis was May 3, 2019. PFS was
investigator-assessed per Response Evaluation Criteria in Solid Tumors
(RECIST) v1.1. The current exploratory analysis evaluated PFS in
the veliparib-throughout arm and the control arm, in patients
with conﬁrmed BRCAwt (wild type) with and without HRD (HRD/
BRCAwt and HRP, respectively), for whom a GIS could be obtained
(Supplementary Fig. S1).
PFS was also analyzed in the veliparib-throughout, veliparibcombination only, and control arms, in patients with stable disease
(SD) following combination treatment, regardless of BRCA status
(Supplementary Fig. S1). The analysis of progression-free survival
(PFS) in patients with SD at the end of the combination phase included
BRCAm (mutation) and BRCAwt patients with measurable disease
assessed by RECIST v1.1 as well as patients with nonmeasurable disease.
In patients with nonmeasurable disease, overall response was categorized as complete response (CR), progressive disease (PD), non-CR/
non-PD, or not evaluable. Patients undergoing interval surgery had a
tumor baseline reassessment after surgery; therefore, response was
considered for 3 cycles. PFS since randomization was compared between all 3 treatment arms.

3. Results
3.1. Patients
A total of 1140 patients were randomized in the VELIA study; baseline demographics and clinical characteristics were broadly balanced
between treatment arms and have been previously published, together
with PFS in BRCAm and HRD cohorts, as well as the whole (entire) population [15]. The primary study endpoints evaluated PFS between the
veliparib-throughout and control arms.
3.2. Correlation of PFS and GIS in biomarker-deﬁned subgroups within the
BRCAwt population

2.4. CA-125 response endpoints and assessments
CA-125 levels were measured as a marker of response to therapy
[20] at baseline and Day 1 of each treatment cycle during the combination phase (Cycles 1–6) using standard methodology at local laboratories. CA-125 response was deﬁned as ≥90% reduction from baseline, in
line with previously published studies [21–23]. A conﬁrmatory value
was not required. CA-125 response was calculated in both BRCAm and
BRCAwt subgroups using the change in CA-125 levels from baseline to
each analysis timepoint. This includes patients with interval
cytoreductive surgery (Supplementary Fig. S1).

BRCAwt patients (N = 742) were grouped according to tumor HRD
status: 373 patients had HRP (low GIS, <33) tumors and 329 patients
had HRD/BRCAwt (high GIS, ≥33) tumors; there were 40 patients with
unknown GIS (Supplementary Fig. S1). Baseline demographic and clinical characteristics for the HRP and HRD/BRCAwt subgroups are listed in
Table S1.
Median PFS was compared between the veliparib-throughout arm
and the control arm (as per the primary endpoint analysis) in both
HRD/BRCAwt and HRP subgroups (Fig. 1). Overall, median PFS was longer
in the HRD/BRCAwt group compared with the HRP subgroup, but HRs between the veliparib-throughout and control arms were similar for both
groups (HRD/BRCAwt: 22.9 vs 19.8 months; hazard ratio 0.76; HRP:
15.0 vs 11.5 months; hazard ratio 0.765, with veliparib-throughout vs
control, respectively; Fig. 1A, Supplementary Fig. S2), suggesting beneﬁts
of veliparib treatment were similar in both subgroups.
Evaluation of mPFS HRs between the primary study arms across a
continuum of GIS in the BRCAwt population revealed similar veliparib
treatment effect across all GIS, including HGSC with high GIS as well as
those with very low GIS (Fig. 1B). Moving the GIS cutoff from 33 to 42,
a GIS cutoff used in other PARPi trials, did not change this observation.

2.5. Radiographic response endpoints and assessments
Radiographic response during treatment Cycles 1–6 was assessed at
baseline and then every 9 weeks in all patients. Imaging scans were reviewed by the investigator. Objective response rate (ORR; CR + partial
response [PR]) at the end of the combination phase was calculated per
RECIST v1.1 only for patients who had measurable residual disease following primary cytoreductive surgery, within the whole population
and in subgroups according to BRCA mutation and HRD status. Patients
who underwent interval debulking surgery were not included because
they were re-baselined at the start of Cycle 4 and generally did not
have residual disease after surgery (Supplementary Fig. S1). The end
of the combination phase was deﬁned as 30 days after the last dose of
carboplatin or paclitaxel, and the last postbaseline tumor assessment
within this window was used to determine response.

3.3. Veliparib in combination with chemotherapy: CA-125 response analysis
The main CA-125 response analysis included all patients (BRCAm
and BRCAwt) with evaluable CA-125 measurements and pooled data
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Fig. 1. (A) Kaplan−Meier curves of PFS in HRP and HRD/BRCAwt and patient subgroups. (B) PFS beneﬁt in HRP and HRD/BRCAwt patient subgroups.
The black line represents hazard ratio and grey shading indicates 95% CI. Abbreviations: BRCAwt, BRCA wild type; CI; conﬁdence interval; GIS, genomic instability score; HRD, homologous
recombinant deﬁcient; HR, homologous recombination; HRP, homologous recombinant proﬁcient; PFS, progression-free survival.

pooled veliparib and control arms for the remainder of the combination
phase (56% vs 51% on Day 1 of Cycle 7; P = 0.179). For the subgroup of
patients undergoing neoadjuvant chemotherapy, CA-125 responses up
to interval surgery (Day 1 of Cycle 3) were 51% (95/187) and 37% (37/
100) in the pooled veliparib and control arms, respectively (P =
0.017) (Fig. 2A).
CA-125 responses in biomarker-deﬁned subgroups according to
BRCA mutation status and HRD status are shown in Fig. 2 and Supplementary Fig. S3. The proportion of patients achieving CA-125 responses
was generally higher in the pooled veliparib arms compared with the
control arm. Of note, this difference was most evident at Cycle 3 in the
BRCAwt and HRP subgroups (pooled veliparib vs control arm: 31% vs

from patients in the veliparib-containing arms because they received
the same treatment for the ﬁrst 6 cycles. Table 1 shows the baseline
characteristics for the pooled veliparib-containing (N = 765) and control arms (N = 375), including 213 and 107 patients in each arm, respectively, who received interval surgery; molecular characteristics
were balanced, and CA-125 was elevated (according to local laboratory
deﬁnitions) at baseline in the majority of patients.
By Day 1 of Cycle 3 in the combination phase, the proportion of patients with a CA-125 response deﬁned as ≥90% reduction (regardless
of surgery type) was higher in the pooled veliparib arm relative to the
control arm (34% vs 23% of patients, respectively; P = 0.0004; Supplementary Fig. S3A). CA-125 response rates were similar between the
248
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3.5. PFS in patients with stable disease following combination treatment

Table 1
Key patient characteristics in the veliparib-containing pooled arms and control arm of the
VELIA study (CA-125 and radiographic response analysis).
Characteristic

Veliparib-containing
arms (pooled)
(n = 765)

Age, median (range), years
62 (22–88)
Age distribution, n (%)
<65 years
454 (59.3)
≥65 years
311 (40.7)
Geographic region, n (%)
North America
528 (69.0)
Japan
55 (7.2)
Rest of world
182 (23.8)
ECOG status, n (%)
0
434 (57.6)
≥1
319 (42.4)
Unknown
12
Stage of disease, n (%)a
Stage III
583 (76.3)
Stage IV
181 (23.7)
b,c
Surgery received, n (%)
Primary
514 (67.2)
Interval
213 (27.8)
None
38 (5.0)
Residual disease after primary surgery, n/N (%)
No residual disease
242/514 (47.1)
Microscopic residual disease only
100/514 (19.5)
Any macroscopic residual disease
172/514 (33.5)
Residual disease after interval surgery, n/N (%)
No residual disease
91/206 (44.2)
Microscopic residual disease only
54/206 (26.2)
Any macroscopic residual disease
61/206 (29.6)
Unknown
7
Biomarker status,d,e n (%)
BRCAm
206 (29.7)
BRCAwt (includes HRD and HRP)
488 (70.3)
HRD (includes BRCAm and
420 (62.9)
BRCAwt)
HRD/BRCAwt
214 (32.0)
HRP
248 (37.1)
CA-125 status, n (%)
Baseline CA-125 > ULNf
642 (85.3)

At the end of the combination phase, 28% (n = 104) of patients in
the control arm, 23% (n = 89) in the veliparib-combination–only
arm, and 21% (n = 82) in the veliparib-throughout arm had SD for
those with measurable disease, or non-CR/non-PD for those with
only nonmeasurable disease (Fig. S4). These patients are typically
not eligible for PARPi maintenance therapy, but were allowed to continue maintenance in this study. Baseline characteristics for these patients are shown in Table S3. Notably, fewer patients in the veliparib
combination-only arm have Stage IV disease than in the control and
veliparib-throughout arms, and fewer patients in the control arm
had a BRCA mutation than in the veliparib arms. A waterfall plot
illustrating the change in tumor size from baseline in each arm is
shown in Fig. S4A. Median PFS in patients with SD following combination treatment was 13 months for the control arm, 14 months
for the veliparib-combination–only arm (hazard ratio 1.03; 95% CI
0.72 to 1.47 vs control), and 16 months for the veliparib-throughout
arm (hazard ratio 0.79; 95% CI 0.54 to 1.16 vs control; Fig. S4B).
At Month 10, the PFS rate was 83% for the veliparib-throughout
arm, 78% in the veliparib-combination–only arm, and 73% in the
control arm.

Control arm
(n = 375)
62 (33–86)
233 (62.1)
142 (37.9)
266 (70.9)
23 (6.1)
86 (22.9)
226 (60.9)
145 (39.1)
4
292 (78.1)
82 (21.9)
250 (66.7)
107 (28.5)
18 (4.8)
116/250 (46.4)
58/250 (23.2)
76/250 (30.4)

4. Discussion
VELIA is the ﬁrst Phase 3 trial to evaluate PARP inhibition in newly
diagnosed patients with advanced HGSC regardless of BRCA status, surgical management, or response to platinum therapy. This distinguishes
VELIA from other reported primary maintenance trials in HGSC in that
it enrolled a broader patient population. The results of these exploratory
analyses of PFS within the BRCAwt population suggest that veliparib
provided a similar improvement in PFS compared with placebo regardless of tumor HRD status. Median PFS was also generally longer for patients with BRCAwt/HRD cancers relative to those with HRP cancers,
regardless of study arm. Taken together, these data indicate that the
GIS may be a prognostic marker of PFS regardless of treatment arm;
however, GIS is not a predictive marker of response to veliparib. That
GIS is not a predictive marker represents an important ﬁnding because
patients with HRP cancers may still derive beneﬁt from the veliparibthroughout regimen. A PFS beneﬁt with the veliparib-throughout regimen versus control was observed across a range of GIS, including patients whose cancers had a GIS as low as 0–10. The lack of a difference
between the hazard ratios across treatment arms for HRD/BRCAwt and
HRP cancers is unique to VELIA, differing from other PARPi maintenance
trials of HGSC both in the recurrent and frontline settings [5,24]. In previous studies of PARPi as maintenance therapy [5,6], a GIS cutoff of 42
was used. The rationale for using a cutoff of 33 in VELIA was based on
ﬁndings reported by Hodgson et al., [19] wherein the threshold of 33
aimed to exclude patients who were least likely to beneﬁt from PARPi.
Because we found no GIS cutoff that separated those in whom a
veliparib treatment beneﬁt was not seen (i.e., to deﬁne HRD and HRP
subgroups), we conclude that using a cutoff of 33 was not responsible
for the lack of predictive ability for the test within VELIA.
To explore whether the addition of veliparib to chemotherapy contributed to eliminating the difference in hazard ratios between HRD
and HRP cancers, we used CA-125 as a sensitive measure of tumor regression in BRCAm and BRCAwt cases. CA-125 responses occurred earlier in the veliparib-containing treatment arms compared with the
control arm. Likewise, in the neoadjuvant setting a higher proportion
of patients in the veliparib arms than in the control arm had CA-125 responses after the ﬁrst two cycles of chemotherapy (prior to interval
debulking surgery). CA-125 responses have been previously associated
with improved surgical and response outcomes [21]; however, in our
analysis the placebo arm caught up in CA-125 response by the end of
chemotherapy and the clinical signiﬁcance of this CA-125 decrease is
uncertain.

50/103 (48.5)
22/103 (21.4)
31/103 (30.1)
4
92 (26.6)
254 (73.4)
207 (62.5)
115 (34.7)
124 (37.5)
316 (85.6)

Abbreviations: CA-125, cancer antigen 125; BRCAm, BRCA mutation; BRCAwt, BRCA wild
type; ECOG, Eastern Cooperative Oncology Group; HRD, homologous recombination deﬁcient; HRP, homologous recombination proﬁcient; ULN, upper limit of normal.
All percentages are calculated on nonmissing values.
a
Status unknown for 1 patient in each arm.
b
68% of all primary surgeries were gross resection.
c
70% of all interval surgeries were gross resection.
d
BRCA status unknown for 71 patients (veliparib pooled) and 29 patients (control).
e
HRD status unknown for 97 patients (veliparib pooled) and 44 patients (control).
f
All evaluable, status unknown for 12 patients (veliparib pooled) and 6 patients
(control).

22% and 28% vs 14%, respectively; Figs. 2C and S3D) as compared with
more similar proportions in the biomarker-selected subgroups,
i.e., those with HRD and BRCAm tumors (pooled veliparib vs control
arm: 35% vs 30% and 36% vs 27%, respectively; Figs. S3B and 2B).
3.4. Veliparib in combination with chemotherapy: Radiographic response
analysis
Baseline characteristics for patients with measurable disease after
primary surgery (n = 290) were generally similar to the overall population and between treatment arms (Table S2; Table 1). At the end
of the combination phase, CRs were seen in 24% (95% CI 18.4 to
30.4) of patients in the pooled veliparib arms and 18% (95% CI 10.4
to 26.1) of patients in the control arm in the overall population.
Response rates per RECIST v1.1 for each of the biomarker-selected
and -unselected subgroups are shown in Fig. 3; ORR in the HRP subgroup was generally lower than in biomarker-positive subgroups
and the whole population.
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Fig. 2. CA-125 response during the combination phase in (A) BRCAm and BRCAwt patients receiving interval debulking surgery, and in (B) BRCAm and (C) BRCAwt subgroups regardless of
surgery type. Abbreviations: BRCAm, BRCA mutated; BRCAwt, BRCA wild type; CA-125, cancer antigen 125.
*P < 0.05. CA-125 was measured on Day 1 of each cycle, thereby reﬂecting the previous cycle.

combined therapy phase were eligible to receive veliparib (or placebo,
according to randomization) in the maintenance setting in VELIA; this
resulted in an extra 21%–28% of patients in each arm being eligible for
maintenance treatment, in contrast to other PARPi maintenance trials.
It should be noted that these analyses were exploratory in nature
and hypothesis-generating; sample sizes also preclude a conclusive interpretation of the data. Furthermore, a lack of PFS difference for the
veliparib arm without maintenance calls into question the clinical signiﬁcance of these ﬁndings. However, these ﬁndings may explain the
similar PFS hazard ratios in VELIA for HRD/BRCAwt and HRP HGSC.
The veliparib combination phase may have improved the overall outcomes speciﬁcally for the HRP patients, including those who would
not have qualiﬁed for other PARPi maintenance trials because of inadequate platinum response. Alternative explanations for the different behavior of the HRD biomarker in VELIA relative to other studies include
differences in selection criteria between trials, differences in the design
of the control arms in the maintenance phase (eg, the PAOLA study used
bevacizumab in combination with chemotherapy) [5,6], the very low
event rate during chemotherapy in general, or variation in the mode
of action of different PARPi [27].
Overall, HRD has some utility in terms of relative risk and prognostic
expectations, but its use to inform who to treat or not treat with
veliparib is limited.

Notably, the CA-125 analyses showed a trend toward a higher response rate with the addition of veliparib primarily in HRP cancers,
with a smaller beneﬁt seen in the HRD/BRCAwt subgroup. One
hypothesis is that HRD cancers are already highly sensitive to
platinum-based chemotherapy [25], and their response is not further
augmented by adding veliparib, whereas the addition of veliparib
produces a more prominent effect in HRP cancers. While higher CA125 responses have been reported in HRD/BRCAwt HGSC treated
with PARPi or chemotherapy [26], VELIA uniquely combined chemotherapy with a PARPi inhibitor. These results provide rationale for
further exploration of veliparib in combination with chemotherapy
in patients with HRP cancers.
To corroborate the CA-125 response ﬁndings, we assessed radiographic ORR after the chemotherapy combination phase in BRCAm
and BRCAwt patients, acknowledging the limitations associated with
volumetric analysis and the application only to patients with measurable disease after primary surgery. We demonstrate that during the
combination phase, addition of veliparib to chemotherapy led to numerically higher radiographic response rates relative to chemotherapy
alone. The higher rates of CR observed across the ITT population support
a potential beneﬁt of veliparib added to chemotherapy in higher risk patients with measurable disease after primary cytoreductive surgery. In
addition, patients without disease progression at the end of the
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Fig. 3. ORR at the end of the combination phase in (A) all patients with primary surgery and measurable disease and in the (B) all HRD, (C) BRCAm, (D) HRD/BRCAwt, and (E) HRP
subgroups.
Abbreviations: BRCAm, BRCA mutated; BRCAwt, BRCA wild type; CR, complete response; HRD, homologous recombination deﬁcient; HRP, homologous recombinant proﬁcient; ORR,
objective response rate; PR, partial response

5. Conclusion

Data sharing statement

Our data demonstrate that the VELIA regimen is effective in various
subgroups of HGSC, obviating the question of when and whether to use
HRD testing before PARPi maintenance, and potentially broadening the
application of PARPi therapy in HGSC that would not have been sufﬁciently chemo-responsive to qualify for maintenance in other frontline
PARPi trials.

AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual,
and trial-level data (analysis data sets), as well as other information
(eg, protocols and Clinical Study Reports), as long as the trials are not
part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
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